Celyad Oncology S.A.
CYAD.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €29 | €10 | €11 | €55 |
| - Cash | €4 | €7 | €12 | €30 |
| + Debt | €18 | €1 | €0 | €3 |
| Enterprise Value | €43 | €4 | -€1 | €27 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 82.4% | – | – | – |
| Gross Profit | €1 | €0 | -€1 | -€2 |
| % Margin | 494.1% | 32.4% | – | – |
| EBITDA | -€5 | -€8 | -€40 | -€25 |
| % Margin | -2,898.4% | -7,610.8% | – | – |
| Net Income | -€6 | -€8 | -€41 | -€27 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| Operating Cash Flow | -€6 | -€15 | -€28 | -€27 |
| Capital Expenditures | -€0 | -€1 | -€0 | -€0 |
| Free Cash Flow | -€6 | -€16 | -€28 | -€27 |